Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 27, 2026

FullPAC, Inc. Issues Spring 2026 Chairman’s Letter

View original at globenewswire.com
FullPAC, Inc. Issues Spring 2026 Chairman’s Letter Virginia Beach, VA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- FullPAC, Inc. (“FullPAC” or the “Company”) (Nasdaq Reserved: GOTV), a premier nonpartisan campaign technology provider for more than 5,000 U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FullPAC is well positioned to serve the growing political spending market as campaign investment builds ahead of the 2028 Presidential election

    80% confidence

  • Advocacy Lab contributes meaningful recurring revenue and serves as a natural entry point into the broader FullPAC platform, strengthening client retention and expanding long-term revenue opportunities

    80% confidence

  • FullPAC is positioned to become the premier public-market pure play on America's growing political campaign industry

    80% confidence

  • Cash flows from Advocacy Lab will cover its direct purchase consideration by March 31, 2026, several months ahead of schedule

    80% confidence

  • Political campaign spending has surged ever higher since Citizens United was decided in 2010

    80% confidence

  • The 2026 election cycle's projected $10.8 billion advertising spending makes it the most expensive non-presidential election cycle in history, marking a more than 20% increase over 2022 midterms

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com